SCF ENCYCLOPEDIA ENTRY

SCF-RDOS INDICATION REGISTRY

POSTPARTUM STRESS-INDUCED CARDIOMYOPATHY

SCF-RDOS Registry Code: SCF-RDOS-PPD-CV-006

ICD Alignment: Stress-Induced Cardiomyopathy (Takotsubo Cardiomyopathy) Associated with Pregnancy and the Postpartum Period

SCF Classification: Postpartum Cardiovascular Disease

SCF Disease Domain: Maternal Neurocardiac Stress Response Syndrome

SCF Pathogenesis Tier: Tier IV–VI Neurocardiovascular Failure Disorder

Clinical Category: Postpartum Stress-Mediated Myocardial Dysfunction Syndrome

SCF Clinical Priority Level: High to Critical

FDA Therapeutic Area: Cardiovascular Disease / Cardiomyopathy

1. DEFINITION

Postpartum Stress-Induced Cardiomyopathy (PSIC), commonly referred to as Takotsubo Cardiomyopathy, is an acute and usually reversible myocardial dysfunction syndrome characterized by transient left ventricular systolic impairment occurring in the absence of obstructive coronary artery disease.

The condition is triggered by profound emotional, physical, neuroendocrine, or obstetric stressors occurring during labor, delivery, or the postpartum period.

Within the SCF framework, Postpartum Stress-Induced Cardiomyopathy is classified as:

A neurocardioendocrine myocardial stunning syndrome arising from acute catecholaminergic overload, autonomic dysregulation, mitochondrial bioenergetic collapse, microvascular dysfunction, and transient myocardial contractile failure.

2. SCF ETIOPATHOGENIC CORE

Primary Disease Drivers

Catecholamine Storm

Excessive release of:

• Epinephrine
• Norepinephrine
• Dopamine

Results in:

• Myocardial stunning
• Microvascular dysfunction
• Direct cardiomyocyte toxicity

Neuroendocrine Stress Response

Triggers include:

• Difficult labor
• Obstetric hemorrhage
• Emergency cesarean section
• Severe pain
• Emotional trauma
• Maternal anxiety

Autonomic Dysregulation

Characterized by:

• Sympathetic hyperactivation
• Parasympathetic withdrawal
• Neurocardiac desynchronization

Microvascular Dysfunction

Associated with:

• Coronary microvascular spasm
• Endothelial dysfunction
• Impaired myocardial perfusion

Mitochondrial Dysfunction

Results in:

• ATP depletion
• Oxidative stress
• Impaired contractility

3. SCF FAULT ARCHITECTURE

4. CLINICAL SUBTYPE REGISTRY

SCF-RDOS-PPD-CV-006A

Classic Apical Takotsubo Syndrome

Features:

• Apical ballooning
• Hypercontractile basal segments

Most common subtype.

SCF-RDOS-PPD-CV-006B

Midventricular Takotsubo Syndrome

Features:

• Midventricular hypokinesis
• Preserved apical contraction

SCF-RDOS-PPD-CV-006C

Basal (Reverse) Takotsubo Syndrome

Features:

• Basal hypokinesis
• Hypercontractile apex

More frequently observed in younger women.

SCF-RDOS-PPD-CV-006D

Focal Takotsubo Syndrome

Features:

• Localized ventricular dysfunction
• Limited myocardial involvement

SCF-RDOS-PPD-CV-006E

Global Takotsubo Syndrome

Features:

• Diffuse ventricular dysfunction
• Extensive myocardial stunning

5. MOLECULAR MULTI-OMICS PATHOGENESIS MAP

Genomics

Potential susceptibility genes:

Adrenergic Signaling

• ADRB1
• ADRB2
• ADRB3

Stress Response

• COMT
• MAOA
• SLC6A4

Cardiomyocyte Resilience

• BAG3
• TTN
• HSP family genes

Transcriptomics

Upregulated pathways:

• Adrenergic signaling
• TNF-α
• IL-6
• Oxidative stress pathways

Downregulated pathways:

• Mitochondrial biogenesis
• Energy metabolism pathways

Proteomics

Abnormal proteins include:

• Stress response proteins
• Heat shock proteins
• Sarcomeric regulatory proteins

Result:

• Contractile dysfunction
• Myocardial stunning

Metabolomics

Characteristic findings:

• ATP depletion
• Increased catecholamine metabolites
• Lactate accumulation
• Oxidative stress products

Epigenomics

Potential contributors:

• Stress-induced gene regulation
• Neuroendocrine transcriptional remodeling

Interactomics

Affected pathways:

• β-adrenergic signaling
• cAMP pathways
• Calcium handling pathways
• PI3K/AKT signaling
• Nitric oxide pathways

Connectomics

Major abnormalities:

• Limbic-cardiac signaling dysregulation
• Sympathetic overactivation
• Vagal suppression

Biomechanicalomics

Observed changes:

• Regional ventricular wall-motion abnormalities
• Ventricular strain heterogeneity
• Transient ventricular remodeling

6. SCF PATHOGENESIS FLOW

Stage 1 — Acute Postpartum Stress Event

Physical or emotional stressor

↓

Stage 2 — Neuroendocrine Activation

Hypothalamic stress response

↓

Massive catecholamine release

↓

Stage 3 — Catecholamine Toxicity

Adrenergic receptor overstimulation

↓

Calcium dysregulation

↓

Stage 4 — Microvascular Dysfunction

Coronary microvascular spasm

↓

Reduced myocardial perfusion

↓

Stage 5 — ATP Collapse

Mitochondrial dysfunction

↓

Oxidative stress

↓

Stage 6 — Ventricular Stunning

Transient systolic dysfunction

↓

Regional wall-motion abnormalities

↓

Stage 7 — Clinical Cardiomyopathy

Chest pain

↓

Heart failure symptoms

↓

Arrhythmias

↓

Cardiogenic shock (severe cases)

7. CLINICAL PRESENTATION

Common Symptoms

• Acute chest pain
• Dyspnea
• Palpitations
• Fatigue
• Orthopnea

Cardiovascular Manifestations

• Heart failure symptoms
• Hypotension
• Pulmonary edema

Severe Presentations

• Ventricular arrhythmias
• Cardiogenic shock
• Sudden cardiac arrest
• Thromboembolic complications

8. DIAGNOSTIC BIOMARKERS

Cardiac Biomarkers

Typically elevated:

• Troponin I
• Troponin T
• BNP
• NT-proBNP

Usually disproportionate to the degree of ventricular dysfunction.

Electrocardiography

Possible findings:

• ST-segment elevation
• ST-segment depression
• T-wave inversion
• QT prolongation

Echocardiography

Typical findings:

• Apical ballooning
• Regional wall-motion abnormalities
• Reduced ejection fraction

Cardiac MRI

Demonstrates:

• Myocardial edema
• Absence of infarction pattern
• Reversible myocardial injury

Coronary Angiography

Usually reveals:

• No obstructive coronary artery disease

9. SCF THERAPEUTIC MECHANISMS

A. SCF-PCR PREVENTATIVE MODULE

Objectives

Reduce postpartum neurocardiac stress vulnerability.

Targets:

• Stress-response pathways
• Autonomic imbalance
• Oxidative stress
• Endothelial dysfunction

B. SCF-PCR CURATIVE MODULE

Objectives

Stabilize myocardial function during acute illness.

Targets:

• Catecholamine toxicity
• Ventricular dysfunction
• Microvascular impairment
• Neurohormonal activation

Clinical interventions may include:

• Hemodynamic support
• Heart failure management
• Arrhythmia management
• Stress-response stabilization

C. SCF-PCR RESTORATIVE MODULE

Objectives

Promote complete myocardial recovery.

Targets:

• Mitochondrial restoration
• Ventricular remodeling reversal
• Neurocardiac synchronization
• Endothelial recovery

Potential strategies:

• Precision cardiac rehabilitation
• Autonomic retraining programs
• Regenerative cardiac therapeutics

10. RESISTANCE & OFF-TARGET MODELING

11. PROGNOSTIC STRATIFICATION

Low Risk

• Rapid ventricular recovery
• Minimal complications
• Preserved cardiac reserve

Intermediate Risk

• Persistent ventricular dysfunction
• Recurrent hospitalization
• Moderate arrhythmia burden

High Risk

• Cardiogenic shock
• Severe heart failure
• Ventricular arrhythmias
• Left ventricular thrombus
• Multiorgan hypoperfusion

12. SCF THERAPEUTIC TARGET MAP

13. PROJECT RHENOVA INTEGRATION PATHWAYS

RHENOVA-CARDIO-TAKO

Module A

Maternal neurocardiac stress-response atlas.

Module B

Catecholamine toxicodynamics mapping.

Module C

Autonomic-connectomic postpartum analysis.

Module D

Microvascular dysfunction and myocardial stunning modeling.

Module E

Precision neurocardiovascular therapeutic engineering.

14. NEXT STRATEGIC RESEARCH PATHWAYS

Priority 1

Postpartum stress-cardiomyopathy multi-omic atlas.

Priority 2

Neurocardiac biomarker discovery platform.

Priority 3

Catecholamine injury mitigation therapeutics.

Priority 4

Autonomic dysfunction prediction systems.

Priority 5

SCF-derived myocardial resilience and recovery API development program.

SCF-RDOS INDICATION SUMMARY